API Development_Intas_GB

Intas’ strength is fuelled by early identification of molecules, building a robust API processes and targeting early launch opportunities in key markets through complete backward integration. Intas manufactures APIs covering a wide gamut of therapeutic areas like Oncology, Central Nervous System, Diabetology, Cardiology and more. More than 90% of the APIs manufactured are used for captive consumption.

Intas’ first API manufacturing facility was setup in 2007 with a vision of developing high quality and cost-effective products through indigenous R&D as import substitutes. Today, Intas’ API manufacturing facilities span four different locations and are accredited by stringent global regulatory authorities like USFDA, MHRA, AFFSAPS (France), COFEPRIS (Mexico) and several others, which reinforces its global quality standards. Today, Intas’ APIs are considered to be of global standards and is being used to manufacture finished products to supply highly regulated markets. The company’s current manufacturing capacity is 35 MT/Annum for Oncology APIs and 70 MT/Annum for General APIs.

Watch jobs in this category